[Skip to Content]
[Skip to Content Landing]
May 1976

To the Editor.—

Author Affiliations

Yale Univ School of Med New Haven, CT 06510

Arch Neurol. 1976;33(5):374-375. doi:10.1001/archneur.1976.00500050060020

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


I read Norris's article with interest and some confusion. There are several inconsistencies. The major one concerns the conclusion (I would draw attention to the paragraph in the "Results" section on page 71, "Neurologic Deficit"): "The mean percentage improvement in neurologic deficit scores between day 1 and day 29 in the surviving patients was 35.6%... in the steroid group and 16.7%... in the placebo group. This difference is statistically significant... indicating that patients receiving steroid therapy did not fare as well as patients receiving only placebo." Unless the figures have been reversed (as suggested by Table 3), this changes the entire point of the article.

There are a few other minor points. While there were 53 patients in the whole study, there were not 27 in the placebo group but rather 24, and there were not 26 in the steroid group but rather 29.

In assessing the effect of

First Page Preview View Large
First page PDF preview
First page PDF preview